Market Place
Sourcing Support
Savara Announces Participation in Upcoming Healthcare Conferences
13 Nov 2024 //
BUSINESSWIRE
Savara Reports Q3 2024 Financial Results & Business Update
12 Nov 2024 //
BUSINESSWIRE
Savara to Present at Guggenheim Healthcare Innovation Conf
04 Nov 2024 //
BUSINESSWIRE
Savara`s aPAP Highlighted On “The Balancing Act®” Airing
22 Oct 2024 //
BUSINESSWIRE
Savara backs talk show episode to boost rare disease awareness
22 Oct 2024 //
FIERCE PHARMA
Savara Announces New Employment Inducement Grant
18 Oct 2024 //
BUSINESSWIRE
Savara`s aPAP Patient Journey Map Accepted For CHEST 2024 Poster
01 Oct 2024 //
BUSINESSWIRE
Savara Announces Expanded Access Program For Molgramostim
27 Sep 2024 //
BUSINESSWIRE
Savara Announces New Employment Inducement Grant
27 Sep 2024 //
BUSINESSWIRE
Savara Names Braden Parker as Chief Commercial Officer
24 Sep 2024 //
BUSINESSWIRE
Savara to Host Analyst and Investor Webinar on September 30, 2024
23 Sep 2024 //
BUSINESSWIRE
Savara Presents IMPALA-2 Trial Data On Molgramostim For aPAP At ERS
08 Sep 2024 //
BUSINESSWIRE
Savara Announces New Employment Inducement Grant
06 Sep 2024 //
BUSINESSWIRE
Savara to Present at H.C. Wainwright Global Investment Conference
03 Sep 2024 //
BUSINESSWIRE
Savara Announces New Employment Inducement Grant
16 Aug 2024 //
BUSINESSWIRE
Savara To Present Phase 3 Data On Molgramostim At 2024 ERS Congress
15 Aug 2024 //
BUSINESSWIRE
Savara Reports Q2 2024 Results And Provides Business Update
12 Aug 2024 //
BUSINESSWIRE
Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock
28 Jun 2024 //
BUSINESSWIRE
Savara Announces Molgramostim Nebulizer Achieved Significance In IMPALA-2 Trial
26 Jun 2024 //
BUSINESSWIRE
Savara to Host Investor Call on IMPALA-2 Trial Results for Molgramostim in aPAP
25 Jun 2024 //
BUSINESSWIRE
Savara to Present at the Jefferies Global Healthcare Conference
29 May 2024 //
BUSINESSWIRE
Savara Presents New aPAP Data At ATS 2024
19 May 2024 //
BUSINESSWIRE
Savara Announces New Employment Inducement Grant
16 May 2024 //
BUSINESSWIRE
Savara Reports First Quarter 2024 Financial Results and Provides Business Update
09 May 2024 //
BUSINESSWIRE
Savara to Present at the Citizens JMP Life Sciences Conference
07 May 2024 //
BUSINESSWIRE
Savara to Present New Data on aPAP at the ATS International Conference 2024
08 Apr 2024 //
BUSINESSWIRE
Savara Announces New Employment Inducement Grant
22 Mar 2024 //
BUSINESSWIRE
Savara Reports Fourth Quarter/Year-End 2023 Financial Results
07 Mar 2024 //
BUSINESSWIRE
Savara to Present at the Barclays 26th Annual Global Healthcare Conference
06 Mar 2024 //
BUSINESSWIRE
Savara Announces New Employment Inducement Grant
02 Feb 2024 //
BUSINESSWIRE
Savara Introduces aPAP ClearPath
21 Dec 2023 //
BUSINESSWIRE
Savara Added to the NASDAQ Biotechnology Index
20 Dec 2023 //
BUSINESSWIRE
Savara Announces New Employment Inducement Grant
15 Dec 2023 //
BUSINESSWIRE
Savara to Present at the Piper Sandler 35th Annual Healthcare Conference
21 Nov 2023 //
BUSINESSWIRE
Revance Appoints Erica Jordan as Chief Commercial Officer, Aesthetics
08 Nov 2023 //
BUSINESSWIRE
Savara to Present at the Jefferies London Healthcare Conference
08 Nov 2023 //
BUSINESSWIRE
Savara Announces New Employment Inducement Grant
06 Oct 2023 //
BUSINESSWIRE
Savara to Present at H.C. Wainwright 25th Annual Global Investment Conference
05 Sep 2023 //
BUSINESSWIRE
Savara Reports Second Quarter Financial Results and Provides Business Update
10 Aug 2023 //
BUSINESSWIRE
Savara Announces New Employment Inducement Grant
04 Aug 2023 //
BUSINESSWIRE
Savara Announces Pricing of $80 Million Underwritten Offering of Common Stock
13 Jul 2023 //
BUSINESSWIRE
Savara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgramostim
26 Jun 2023 //
BUSINESSWIRE
Savara Added to Russell 3000® Index
26 Jun 2023 //
BUSINESSWIRE
Savara to Present at the Jefferies Healthcare Conference
02 Jun 2023 //
BUSINESSWIRE
Savara Reports First Quarter Financial Results and Provides Business Update
15 May 2023 //
BUSINESSWIRE
Savara Announces New Employment Inducement Grant
07 May 2023 //
BUSINESSWIRE
Savara Announces New Employment Inducement Grant
31 Mar 2023 //
BUSINESSWIRE
Savara Reports 4Q / Year-End 2022 Financial Results and Provides Business Update
30 Mar 2023 //
BUSINESSWIRE
Savara to Present at the Oppenheimer 33rd Annual Healthcare Conference
06 Mar 2023 //
BUSINESSWIRE
Savara Announces Employment Inducement Grant Under NASDAQ Rule 5635(c)(4)
28 Feb 2023 //
BUSINESSWIRE
Savara Announces New Leadership Appointments
14 Feb 2023 //
BUSINESSWIRE
Savara Announces New Employment Inducement Grant
20 Jan 2023 //
BUSINESSWIRE
Savara Announces New Employment Inducement Grant
22 Nov 2022 //
BUSINESSWIRE
Savara Reports Third Quarter 2022 Financial Results and Provides Business Update
10 Nov 2022 //
BUSINESSWIRE
Savara to Participate in Three Upcoming Investor Conferences
09 Nov 2022 //
BUSINESSWIRE
Savara - New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
14 Sep 2022 //
BUSINESSWIRE
Savara Presented Data at the ERS International Congress 2022
06 Sep 2022 //
BUSINESSWIRE
Savara to Present at H.C. Wainwright 24th Annual Global Investment Conference
01 Sep 2022 //
BUSINESSWIRE
Savara Announces Resignation of Chief Medical Officer
26 Aug 2022 //
BUSINESSWIRE
Savara Reports Second Quarter 2022 Financial Results
11 Aug 2022 //
BUSINESSWIRE
